Estrella Biopharma Announces FDA Clearance of IND Application for Phase I/II Clinical Trial (Starlight-1) of EB103, a CD19-Targeted ARTEMIS® T Cell Therapy, to Patients with B-Cell Lymphomas
Initiation of Phase I/II Clinical Trial (Starlight-1) Expected to Occur in Second Half of 2023 EMERYVILLE, Calif. and NEW YORK, March 9, 2023 /PRNewswire/ -- Estrella Biopharma, Inc. ("Estrella"), a biopharmaceutical company whose mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer with safe, effective therapies, and...
Mallinckrodt Announces Reimbursement Approval in Japan for the CELLEX® Extracorporeal Photopheresis (ECP) System for the Treatment of Chronic Graft Versus Host Disease (cGvHD)
– CELLEX ECP is now available for reimbursement in Japan for patients who are steroid-resistant or -intolerant and suffering from cGvHD – DUBLIN, March 9, 2023 /PRNewswire/ -- Mallinckrodt plc, (NYSE American: MNK) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced that Japan's National Health Insurance (NHI) system has...
Telix to Showcase Additional ZIRCON Phase III Data in Kidney Cancer Imaging and Theranostic Pipeline Developments at EAU
MELBOURNE, Australia, March 9, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces presentations from the Company's carbonic anhydrase IX (CAIX) targeting kidney and bladder cancer programs at the 38th Annual European Association of Urology (EAU) Congress to be held in Milan from 10 – 13 March 2023. Further...
ETAO International Entered Into Standby Equity Purchase Agreement of Up To $150 Million with YA II PN, Ltd.
NEW YORK, March 9, 2023 /PRNewswire/ -- ETAO International Co., Ltd. ("ETAO" or the "Company") announced on February 24, 2023, ETAO and YA II PN, Ltd., a Cayman Islands exempt limited partnership (the "Investor") managed by Yorkville Advisors Global, LP (the "Investment Manager"), entered into a Standby Equity Purchase Agreement (the "SEPA"). The Investor is a fund headquartered...
Decipher Fat Burning: A Breath Analyzer Achieved Funding Goal on Indiegogo in 1 Hour
SINGAPORE, March 9, 2023 /PRNewswire/ -- Singapore-based Tech startup Metanoia Sensing has announced a new breath analyzer 'MetaNose' to help people monitor their fat (lipid) burning status. The device also provides insights into the users' metabolic health risk such as diabetic related conditions. The MetaNose device has been launched on Indiegogo and has reached its funding goal within the first...
BIORCHESTRA Participating in Two Upcoming Therapeutic RNA-Focused Events
CAMBRIDGE, Mass. and DAEJEON, South Korea, March 8, 2023 /PRNewswire/ -- BIORCHESTRA, a biotherapeutics company focused on the treatment of rare and degenerative diseases within the Central Nervous System (CNS) by leveraging its proprietary Brain-Targeting RNAi Nanomedicine (BTRiNTM) technology to combine targeted cell delivery capabilities and proprietary RNA interference (RNAi) chemistries, to develop best-in-category RNAi therapeutics, today announced...
Hovione receives the 2023 CDMO Leadership Award in all six categories and is Champion in Compatibility and Expertise
LISBON, Portugal, March 8, 2023 /PRNewswire/ -- Hovione, the leader in spray drying and particle engineering, won the 2023 CDMO Leadership Award across all six categories – capability, compatibility, expertise, quality, reliability and service across all three groups of respondents (Big Pharma, Small Pharma, and Overall (combined Big and Small Pharma)). Hovione was given additional recognition as a CDMO Leadership...
JW Therapeutics Announces Initiation of Clinical Study of Carteyva® in First-line Treatment in Patients with High-Risk Large B-Cell Lymphoma
SHANGHAI, March 8, 2023 /PRNewswire/ -- JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced the initiation of clinical study of Carteyva® (relmacabtagene autoleucel injection) for first-line treatment in patients with high-risk large B-cell lymphoma and the first patient infusion. High-risk large B-cell lymphoma includes large B-cell lymphoma...
ICP DAS – BMP to show KIMES 2023 visitors high-performance medical TPU pellets in Seoul, Korea
HSINCHU, March 7, 2023 /PRNewswire/ -- ICP DAS - BMP (Biomedical Polymers), a Taiwan medical TPU (thermoplastic polyurethane) supplier, will have its first showcase in KIMES 2023, Korea. Exhibit highlights include TPU pellets with radiopacifiers of 50% tungsten (W50) and 40% Barium Sulfate (B40), respectively. The Medical & Hospital Equipment Show takes...
ONEDAY BIOTECH to unveil ‘One Drilling System’ at IDS 2023
One Drilling System Completing the Implant Procedure with Just One Drilling Exclusively Company Specializing in Implants Pursuing 'One-Day-Completion Implant' SEOUL, South Korea, March 8, 2023 /PRNewswire/ -- ONEDAY BIOTECH (CEO Kim Jin-hwan), a dental product manufacturer specializing in one-day-completion implants system, announced on the 7th that they will showcase outstanding products including One Drilling System that is able...
